

Application No.
Amendment Dated
Page 2 of 7


10/550, c 38
08/23/2006

Amendments to the Claims:

Amendments to the Claims
This listing of claims will replace all prior versions, and listings, of claims in the application.


Claims:

Claims: 1. (Currently Amended) A compound of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof,




(1)

wherein -N-HET is



(Id)

Q is







R_2 and R_3 are independently selected from H, F, Cl, CF_3 , OMe , SMe , Me and Et;

T is selected from the groups in (TAa1) to (TAa12):

Application No.
Amendment Dated
Page 3 of 7

10/550,638
08/23/2006



wherein :

R^{6h} is hydrogen or (1-4C)alkyl;
 R^{4h} and R^{5h} are independently selected from hydrogen, cyano, hydroxy(1-4C)alkyl, cyano(1-4C)alkyl, phosphoryl(1-4C)alkyl, benzyl (optionally substituted on the phenyl ring by one substituent selected from halo, methyl and methoxy), (1-4C)alkyl, (1-4C)alkyl substituted with ORc (wherein Rc is $R^{13}CO$ and R^{13} is selected from Rc2b), (1-4C)alkanoyl and (1-4C)alkoxycarbonyl;

(Rc2b) (1-10C)alkyl

{optionally substituted by one or more groups (including geminal disubstitution) each independently selected from hydroxy, (1-10C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkanoyl, carboxy, phosphoryl [-O-P(O)(OH)₂], and mono- and di-(1-4C)alkoxy derivatives thereof], phosphoryl [-O-P(OH)₂] and mono- and di-(1-4C)alkoxy derivatives thereof], and amino; and/or optionally substituted by one group selected from phosphonate [phosphono, -P(O)(OH)₂, and mono- and di-(1-4C)alkoxy derivatives thereof], phosphinate [-P(OH)₂] and mono- and di-(1-4C)alkoxy derivatives thereof], cyano, halo, phosphinato [-P(OH)₂] and mono- and di-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alkylaminocarbonyl, (1-4C)alkoxycarbonylaminocarbonyl, (1-4C)alkylaminocarbonyl, (1-4C)alkylS(O)pNH-, (1-4C)alkylS(O)p-((1-4C)alkyl)N-, fluoro(1-di((1-4C)alkyl)aminocarbonyl, (1-4C)alkylS(O)pNH-, fluoro(1-4C)alkylS(O)p-((1-4C)alkyl)N-, (1-4C)alkylS(O)q- [the (1-4C)alkyl group of (1-4C)alkylS(O)q- being optionally substituted by one substituent selected from hydroxy, (1-4C)alkoxy, (1-4C)alkanoyl, phosphoryl [-O-P(O)(OH)₂], and mono- and di-(1-4C)alkoxy derivatives thereof], phosphoryl [-O-P(OH)₂] and mono- and di-(1-4C)alkoxy derivatives thereof], amino, cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, carboxy, (1-4C)alkylamino, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkyl-N-(1-di((1-4C)alkyl)amino, (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-di((1-4C)alkyl)amino, (1-4C)alkylS(O)q-]

Application No.
Amendment Dated
Page 4 of 7

10/550,038
08/23/2006

(1-6C) alkanoylamino, (1-4C) alkylaminocarbonyl, di((1-4C) alkyl) aminocarbonyl, (1-4C) alkylS(O)pNH-, (1-4C) alkylS(O)p-((1-4C) alkyl)N-, and (1-4C) alkylS(O)q-((1-4C) alkyl)S(O)pNH-.

2. (Cancelled)


3. (Cancelled)

4. (Previously Presented) The compound of claim 1, wherein R² and R³ are independently

hydrogen or fluoro.

5. (Cancelled)

6. (Previously Presented) The compound of claim 1, which is a compound of formula (IB)



wherein

R² and R³ are independently hydrogen or fluoro;

R^{6h} is hydrogen or (1-4C) alkyl;

R^{4h} and R^{5h} are independently selected from hydrogen, cyano, hydroxy(1-4C) alkyl, cyano(1-4C) alkyl, phosphoryl(1-4C) alkyl, benzyl (optionally substituted on the phenyl ring by one substituent selected from halo, methyl and methoxy), (1-4C) alkyl, (1-4C) alkyl substituted with ORc (wherein Rc is R¹³CO and R¹³ is selected from R^{2b}), (1-4C) alkanoyl and (1-4C) alkoxycarbonyl.

7. (Cancelled)

8. (Previously Presented) A method for producing an antibacterial effect in a warm blooded animal which comprises administering to said animal an effective amount of a compound of claim 1.

9 - 10. (Cancelled)

Application No.
Amendment Dated
Page 5 of 7

10/550,038
08/23/2006

11. (Previously Presented) A pharmaceutical composition which comprises a compound of claim 1, and a pharmaceutically-acceptable diluent or carrier.

12. (Canceled)

13. (Previously Presented) A compound which is
(5R)-3-[3-Fluoro-4-(3-methylisoxazol-5-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;
Ethyl 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl]isoxazole-3-carboxylate;
(5R)-3-[3-Fluoro-4-[3-(hydroxymethyl)isoxazol-5-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;
(5-(2-Fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl)isoxazol-3-yl)methyl dihydrogen phosphate;
1-Methyl-3-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl]-1H-pyrazole-5-carbonitrile;
1-Methyl-3-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl]-1H-pyrazole-5-carbaldehyde;
(5R)-3-[3-Fluoro-4-(1H-1,2,3-triazol-4-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;
(5R)-3-[3-Fluoro-4-(1-methyl-1H-1,2,3-triazol-4-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;
(5R)-3-[3-Fluoro-4-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;
(4-[2-Fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl]-1H-1,2,3-triazol-1-yl)acetonitrile; or
(4-[2-Fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl]-2H-1,2,3-triazol-2-yl)acetonitrile.